{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:18:07Z","timestamp":1793326687791,"version":"4.5.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,1,1]],"date-time":"2016-01-01T00:00:00Z","timestamp":1451606400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,1,3]],"date-time":"2017-01-03T00:00:00Z","timestamp":1483401600000},"content-version":"am","delay-in-days":368,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100000182","name":"U.S. Army Medical Materiel Development Activity, Medical Research and Materiel Command, U.S. Department of Defense","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000182","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2016,1]]},"DOI":"10.1016\/j.vaccine.2015.12.030","type":"journal-article","created":{"date-parts":[[2015,12,22]],"date-time":"2015-12-22T09:46:12Z","timestamp":1450777572000},"page":"424-429","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":43,"title":["Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans"],"prefix":"10.1016","volume":"34","author":[{"given":"Phillip R.","family":"Pittman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"McClain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Quinn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin M.","family":"Coonan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph","family":"Mangiafico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard S.","family":"Makuch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Morrill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clarence J.","family":"Peters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2015.12.030_bib0005","doi-asserted-by":"crossref","first-page":"108","DOI":"10.4172\/2157-2526.1000108","article-title":"Rift Valley fever virus: a real bioterror threat","volume":"2","author":"Mandell","year":"2011","journal-title":"J Bioterror Biodef"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0010","first-page":"124","article-title":"Rift Valley fever vaccine for humans","volume":"3","author":"Eddy","year":"1981","journal-title":"Contr Epidem Biostatist"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0015","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/0264-410X(85)90060-X","article-title":"A Rift Valley fever vaccine trial. 2. Serologic response to booster doses with a comparison of intradermal versus subcutaneous injection","volume":"3","author":"Kark","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0020","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0264-410X(85)90061-1","article-title":"Rift Valley fever virus vaccine trial: study of neutralizing antibody response in humans","volume":"3","author":"Niklasson","year":"1985","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0025","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/S0264-410X(99)00218-2","article-title":"Immonogenicity of an inactivated Rift Valley fever vaccine in humans: a 12 year experience","volume":"18","author":"Pittman","year":"2000","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0030","doi-asserted-by":"crossref","first-page":"405","DOI":"10.4269\/ajtmh.1995.53.405","article-title":"Characterization of clone 13, a naturally attenuated avirulent isolate of Rift Valley fever virus, which is altered in the small segment","volume":"53","author":"Muller","year":"1995","journal-title":"Am J Trop Med Hyg"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.030_bib0035","doi-asserted-by":"crossref","first-page":"e0003550","DOI":"10.1371\/journal.pntd.0003550","article-title":"Randomized controlled field trial to assess the immunogenicity and safety of Rift Valley fever clone 13 vaccine in livestock","volume":"9","author":"Njenga","year":"2015","journal-title":"PLoS Negl Trop Dis"},{"issue":"6","key":"10.1016\/j.vaccine.2015.12.030_bib0040","doi-asserted-by":"crossref","first-page":"2681","DOI":"10.1128\/JVI.02501-07","article-title":"Rift Valley fever virus lacking the NSs and NSm genes is highly attenuated, confers protective immunity from virulent virus challenge, and allows for differential identification of infected and vaccinated animals","volume":"82","author":"Bird","year":"2008","journal-title":"J Virol"},{"issue":"24","key":"10.1016\/j.vaccine.2015.12.030_bib0045","doi-asserted-by":"crossref","first-page":"12901","DOI":"10.1128\/JVI.06046-11","article-title":"Rift Valley fever virus vaccine lacking the NSs and NSm genes is safe, nonteratogenic, and confers protection from viremia, pyrexia, and abortion following challenge in adult and pregnant sheep","volume":"85","author":"Bird","year":"2011","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0050","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1099\/0022-1317-66-10-2271","article-title":"Mutagen directed attenuation of Rift Valley fever as a method of vaccine development","volume":"66","author":"Caplen","year":"1985","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0055","unstructured":"Investigator's brochure: Rift Valley fever vaccine, live, attenuated, mutagenized ZH548, MP-12, TSI-GSD 223. Sponsor: The Surgeon General, Department of the Army. Fort Detrick, MD: U.S. Army Medical Research and Materiel Command (sponsor's representative); 18 January 2012."},{"key":"10.1016\/j.vaccine.2015.12.030_bib0060","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1099\/0022-1317-69-4-817","article-title":"Characterization of attenuated strains of Rift Valley fever virus","volume":"69","author":"Rossi","year":"1988","journal-title":"J Gen Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0065","doi-asserted-by":"crossref","first-page":"278","DOI":"10.4269\/ajtmh.1991.44.278","article-title":"Potential for mosquito transmission of attenuated strains of Rift Valley fever virus","volume":"44","author":"Turell","year":"1991","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0070","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0264-410X(91)90285-E","article-title":"Efficacy of a Rift Valley fever vaccine against aerosol infection in rats","volume":"9","author":"Anderson","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0075","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.2460\/ajvr.1987.48.07.1042","article-title":"Pathogenicity and immunogenicity of a mutagen-attenuated Rift Valley fever virus imunogen in pregnant ewes","volume":"48","author":"Morrill","year":"1987","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0080","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/0264-410X(91)90314-V","article-title":"Further evaluation of a mutagen-attenuated Rift Valley fever vaccine in sheep","volume":"9","author":"Morrill","year":"1991","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0085","doi-asserted-by":"crossref","first-page":"50","DOI":"10.2460\/ajvr.1991.52.01.50","article-title":"Ability of a mutagenized virus variant to protect young lambs from Rift Valley fever","volume":"52","author":"Hubbard","year":"1991","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0090","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1016\/0034-5288(92)90029-2","article-title":"Comparison of the pathogenicity for pregnant sheep of Rift Valley fever virus and a live attenuated vaccine","volume":"52","author":"Baskerville","year":"1992","journal-title":"Res Vet Sci"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0095","first-page":"95","article-title":"Teratogenicity of a mutaganized Rift Valley fever virus (MVP 12) in sheep","volume":"69","author":"Hunter","year":"2002","journal-title":"Onderstepoort J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0100","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.2460\/ajvr.1997.58.10.1104","article-title":"Safety and efficacy of a mutagen-attenuated Rift Valley fever virus vaccine in cattle","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0105","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.2460\/ajvr.1997.58.10.1110","article-title":"Safety of a mutagen-attenuated Rift Valley fever vaccine in fetal and neonatal bovines","volume":"58","author":"Morrill","year":"1997","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0110","doi-asserted-by":"crossref","first-page":"2994","DOI":"10.1016\/S0264-410X(03)00131-2","article-title":"Pathogenicity and neurovirulence of a mutagen-attenuated Rift Valley fever vaccine in rhesus monkeys","volume":"21","author":"Morrill","year":"2003","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0115","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1093\/infdis\/jir249","article-title":"Protection of MP-12-vaccinated rhesus macaques against parenteral and aerosol challenge with virulent Rift Valley Fever virus","volume":"204","author":"Morrill","year":"2011","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0120","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/S0923-2516(89)80086-X","article-title":"Rift Valley fever among animals in the recent West African outbreak","volume":"140","author":"Ksiazek","year":"1989","journal-title":"Res Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0125","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0264-410X(86)90007-1","article-title":"Evaluation of a new Rift Valley fever vaccine: safety and immunogenicity, trials","volume":"4","author":"Meadors","year":"1986","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0130","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1016\/S0923-2516(89)80095-0","article-title":"Filter paper confetti in a serological Rift Valley fever survey","volume":"140","author":"Jouan","year":"1989","journal-title":"Res Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0135","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0923-2516(89)80091-3","article-title":"Rift Valley fever infection of rhesus monkeys: implications for rapid diagnosis of human disease","volume":"140","author":"Morrill","year":"1989","journal-title":"Res Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0140","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1016\/0035-9203(79)90004-X","article-title":"The Rift Valley fever epizootic in Egypt 1977-1978. I. Description of the epizootic and virological studies","volume":"73","author":"Meegan","year":"1979","journal-title":"Trans R Soc Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0145","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/0140-6736(93)92128-G","article-title":"Recurrence of Rift Valley fever in Egypt","volume":"342","author":"Arthur","year":"1993","journal-title":"Lancet"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0150","first-page":"329","article-title":"Rift Valley fever, Yemen (update)","volume":"75","author":"World Health Organization","year":"2000","journal-title":"Wkly Epidemol Rec"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0155","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1001\/jama.284.23.2989","article-title":"Update: outbreak of Rift Valley fever\u2014Saudi Arabia, August\u2013November 2000","volume":"284","author":"Centers for Disease Control","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0160","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1086\/378747","article-title":"Rift Valley fever epidemic in Saudi Arabia: Epidemiological, clinical, and laboratory characteristics","volume":"37","author":"Madani","year":"2003","journal-title":"Clin Inf Dis"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0165","doi-asserted-by":"crossref","first-page":"827","DOI":"10.2174\/156652405774962263","article-title":"Rift Valley fever virus","volume":"5","author":"Flick","year":"2005","journal-title":"Curr Mol Med"},{"issue":"8","key":"10.1016\/j.vaccine.2015.12.030_bib0170","doi-asserted-by":"crossref","first-page":"4204","DOI":"10.1128\/JVI.07104-11","article-title":"Single-dose immunization with virus replicon particles confers rapid robust protection against Rift Valley fever virus challenge","volume":"86","author":"Dodd","year":"2012","journal-title":"J Virol"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0175","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/0264-410X(92)90417-I","article-title":"Strenuous exercise simulating hepatic injury during vaccine trials","volume":"10","author":"Malinoski","year":"1992","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0180","doi-asserted-by":"crossref","first-page":"3222","DOI":"10.1016\/j.vaccine.2011.02.037","article-title":"Immunogenicity and safety of an inactivated Rift Valley fever vaccine in a 19-year study","volume":"29","author":"Rusnak","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0185","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/0264-410X(91)90285-E","article-title":"Efficacy of a Rift Valley fever virus vaccine against an aerosol infection in rats","volume":"9","author":"Anderson","year":"1991","journal-title":"Vaccine"},{"issue":"10","key":"10.1016\/j.vaccine.2015.12.030_bib0190","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.2460\/ajvr.1980.41.10.1559","article-title":"Evaluation of a formalin-inactivated Rift Valley fever vaccine in sheep","volume":"41","author":"Harrington","year":"1980","journal-title":"Am J Vet Res"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0195","first-page":"197","article-title":"Active and passive immunization with Rift Valley fever virus infection in Syrian hamsters","volume":"92","author":"Niklasson","year":"1984","journal-title":"Acta Pathol Microbiol Immunol Scand C"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.030_bib0200","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1128\/jcm.19.3.429-431.1984","article-title":"Protective efficacies of live attenuated and formaldehyde-inactivated Venezuelan equine encephalitis virus vaccines against aerosol challenge in hamsters","volume":"19","author":"Jahrling","year":"1984","journal-title":"J Clin Microbiol"},{"issue":"8","key":"10.1016\/j.vaccine.2015.12.030_bib0205","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1097\/01.jom.0000135539.99691.4e","article-title":"Experience in the medical management of potential laboratory exposures to agents of bioterrorism on the basis of risk assessment at the United States Army Medical Research Institute of Infectious Diseases (USAMRIID)","volume":"46","author":"Rusnak","year":"2004","journal-title":"J Occup Environ Med"},{"issue":"3","key":"10.1016\/j.vaccine.2015.12.030_bib0210","doi-asserted-by":"crossref","first-page":"434","DOI":"10.4269\/ajtmh.13-0264","article-title":"Review article: efficacy and duration of immunity after yellow fever vaccination: systemic review on the need for a booster every 10 years","volume":"89","author":"Gotuzzo","year":"2013","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.vaccine.2015.12.030_bib0215","doi-asserted-by":"crossref","first-page":"5205","DOI":"10.1016\/j.vaccine.2005.07.002","article-title":"Report on a WHO consultation on immunological endpoints for evaluation of new Japanese encephalitis vaccines, WHO, Geneva, 2\u20133 September, 2004","volume":"23","author":"Hombach","year":"2005","journal-title":"Vaccine"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15018216?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X15018216?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T22:13:49Z","timestamp":1748729629000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X15018216"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,1]]},"references-count":43,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,1]]}},"alternative-id":["S0264410X15018216"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.030","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2016,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of a mutagenized, live attenuated Rift Valley fever vaccine, MP-12, in a Phase 1 dose escalation and route comparison study in humans","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2015.12.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}